Literature DB >> 6222679

Patterns of response to inhaled bronchodilators in asthmatics.

P D Paré, L M Lawson, L A Brooks.   

Abstract

In response to inhaled bronchodilators, asthmatic subjects may show a predominant increase in expiratory flow rate (flow responders) or forced vital capacity (volume responders). The pattern of response could relate to the site of expiratory flow limitation and/or the site of action of the inhaled bronchodilator. We studied 15 asthmatic subjects, and measured lung volumes and maximal expiratory flow-volume curves while they breathed room air and 80% He-20% O2 (He-O2) before and after inhalation of fenoterol 400 micrograms (Berotec), and ipratropium bromide 40 micrograms (SCH 1000). Subjects were categorized as flow responders (FR) or as volume responders (VR) by the ratio delta FEV1/delta FVC (ratio less than 1 predominant VR, ratio greater than 1 = predominant FR). The site of expiratory air-flow limitation was assessed by the percent increase in maximal expiratory flow breathing He-O2 at an absolute lung volume (delta Vmax), and the change in He response from control was calculated (delta delta Vmax). The ratio delta FEV1/delta FVC varied between 0 and 10 and did not correlate with initial density dependence. There was no difference in the pattern or apparent site of response to Berotec or SCH 1000. There was a positive relationship between control FEV1 and FVC percent predicted and delta FEV1/delta FVC. The subjects with worse pulmonary function showed a decrease in He-O2 response postbronchodilator and a predominant volume response suggesting recruitment of peripheral diseased airways.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6222679     DOI: 10.1164/arrd.1983.127.6.680

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  4 in total

1.  Possible site of bronchodilation due to inhaled procaterol aerosol in asthmatic patients.

Authors:  O Taguchi; W Hida; H Nogami; H Inoue; T Takishima
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Comparison of the lung function change in patients with COPD and bronchial asthma before and after treatment with budesonide/formoterol.

Authors:  Shao-Yong Gao; Jian-Qiang Huang; Yi-Feng Luo; Zhi-Ping Li; Can-Mao Xie; Yu-Biao Guo
Journal:  J Thorac Dis       Date:  2012-12       Impact factor: 2.895

3.  The synergistic interactions of allergic lung inflammation and intratracheal cationic protein.

Authors:  Jason H T Bates; Ana Cojocaru; Hans C Haverkamp; Lisa M Rinaldi; Charles G Irvin
Journal:  Am J Respir Crit Care Med       Date:  2007-10-25       Impact factor: 21.405

4.  Vital capacity and inspiratory capacity as additional parameters to evaluate bronchodilator response in asthmatic patients: a cross sectional study.

Authors:  Karen S Azevedo; Ronir R Luiz; Patricia Rm Rocco; Marcus B Conde
Journal:  BMC Pulm Med       Date:  2012-09-05       Impact factor: 3.317

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.